WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998032459) PLASMINOGEN ACTIVATOR AS AN ANTI-INFLAMMATORY AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1998/032459 International Application No.: PCT/US1998/001948
Publication Date: 30.07.1998 International Filing Date: 29.01.1998
Chapter 2 Demand Filed: 27.08.1998
IPC:
A61K 38/00 (2006.01) ,A61K 38/49 (2006.01) ,C12N 9/72 (2006.01)
Applicants: STRINGER, Kathleen, A.[CA/US]; US (UsOnly)
HYBERTSON, Brooks, M.[US/US]; US (UsOnly)
REPINE, John, E.[US/US]; US (UsOnly)
McCORD, Joe, M.[US/US]; US (UsOnly)
UNIVERSITY TECHNOLOGY CORPORATION[US/US]; Suite 250 3101 Iris Avenue Boulder, CO 80301, US (AllExceptUS)
Inventors: STRINGER, Kathleen, A.; US
HYBERTSON, Brooks, M.; US
REPINE, John, E.; US
McCORD, Joe, M.; US
Agent: KOKULIS, Paul, N. ; Cushman, Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP 1100 New York Avenue, N.W. Washington, DC 20005, US
Priority Data:
60/036,56629.01.1997US
Title (EN) PLASMINOGEN ACTIVATOR AS AN ANTI-INFLAMMATORY AGENT
(FR) ACTIVATEUR DU PLASMINOGENE UTILISE COMME AGENT ANTI-INFLAMMATOIRE
Abstract:
(EN) Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity, and is not a function of oxygen free radical scavenging. Moreover, in in vivo models of inflammation, treatment with plasminogen activator reduces edema without inhibiting neutrophil infiltration in in vivo models of inflammation.
(FR) L'activateur du plasminogène agit comme un agent anti-inflammatoire en inhibant la production d'anions superoxydes par un mécanisme qui n'est pas en rapport avec la L-arginine, qui n'est pas dépendant de l'activité thrombolytique et qui n'est pas fonction d'un piégeage des radicaux libres oxygène. En outre, dans les modèles in vivo de l'inflammation, le traitement avec l'activateur du plasminogène réduit les oedèmes sans inhiber l'infiltration neutrophile dans les modèles de l'inflammation in vivo.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)